Identification of Liver Tumours Using BIP - Biopsy System
Primary Purpose
Liver Biopsy
Status
Completed
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
BIP Biopsy System
Sponsored by
About this trial
This is an interventional other trial for Liver Biopsy focused on measuring Bioimpedance, Biopsy, Liver tumour, Biopsy needle guidance
Eligibility Criteria
Inclusion Criteria:
- Consenting adults undergoing ultrasound-guided core liver biopsy to diagnose liver tumour or other abnormalities
- Identifiable non-tumorous liver tissue along the planned needle injection path.
Exclusion Criteria:
- Inability to give informed consent
- Being under aged
- Being pregnant
- Being high risk patient
- Lack of identifiable non-tumorous liver tissue along the injection path to the tumour location
- Known contraindications to liver biopsy.
Sites / Locations
- Helsinki University Hospital, Department of Radiology
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
BIP Biopsy System
Arm Description
Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
Outcomes
Primary Outcome Measures
Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue
Liver biopsy is performed in traditional way but with biopsy needle that enables bioimpedance measurement from multiple frequencies (spectrum). Tumorous and nontumorous tissue is measured during ultrasound guided biopsy procedure and the tumorous tissue type is verified by histological biopsy sample analysis. The bioimpedance spectra (impedance and phase angle) are compared with each other and differences in means of the spectra calculated. The data analysis is performed offline.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02620228
Brief Title
Identification of Liver Tumours Using BIP - Biopsy System
Official Title
INJ-LIVERB-01 Identification of Liver Tumours Using BIP - Biopsy System
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
June 9, 2016 (Actual)
Primary Completion Date
December 31, 2017 (Actual)
Study Completion Date
November 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Injeq Ltd
4. Oversight
5. Study Description
Brief Summary
This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP biopsy system is able to distinguish liver tumours from surrounding tissue. In addition, user feedback is obtained to improve the usability of the investigational device. The study does not affect the traditional treatment procedure and only the patients in clinical need for diagnosis by liver biopsy are included on voluntary basis. The invasive products used in actual biopsy operation are designed so that their performance is essentially equal to the currently used biopsy devices, the only difference is the measurement capability of biopsy needle and connection to measurement device.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Biopsy
Keywords
Bioimpedance, Biopsy, Liver tumour, Biopsy needle guidance
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BIP Biopsy System
Arm Type
Experimental
Arm Description
Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
Intervention Type
Device
Intervention Name(s)
BIP Biopsy System
Intervention Description
BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
Primary Outcome Measure Information:
Title
Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue
Description
Liver biopsy is performed in traditional way but with biopsy needle that enables bioimpedance measurement from multiple frequencies (spectrum). Tumorous and nontumorous tissue is measured during ultrasound guided biopsy procedure and the tumorous tissue type is verified by histological biopsy sample analysis. The bioimpedance spectra (impedance and phase angle) are compared with each other and differences in means of the spectra calculated. The data analysis is performed offline.
Time Frame
During liver biopsy (couple of minutes/patient)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Consenting adults undergoing ultrasound-guided core liver biopsy to diagnose liver tumour or other abnormalities
Identifiable non-tumorous liver tissue along the planned needle injection path.
Exclusion Criteria:
Inability to give informed consent
Being under aged
Being pregnant
Being high risk patient
Lack of identifiable non-tumorous liver tissue along the injection path to the tumour location
Known contraindications to liver biopsy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kirsti Numminen, PhD MD
Organizational Affiliation
Helsinki University Hospital, Department of Radiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Helsinki University Hospital, Department of Radiology
City
Helsinki
State/Province
HUS
ZIP/Postal Code
FI-00029
Country
Finland
12. IPD Sharing Statement
Learn more about this trial
Identification of Liver Tumours Using BIP - Biopsy System
We'll reach out to this number within 24 hrs